BidaskClub Upgrades Supernus Pharmaceuticals (SUPN) to “Buy”

Supernus Pharmaceuticals (NASDAQ:SUPN) was upgraded by research analysts at BidaskClub from a “hold” rating to a “buy” rating in a report issued on Wednesday.

A number of other research analysts have also recently weighed in on SUPN. ValuEngine cut shares of Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Friday, June 8th. Piper Jaffray Companies set a $47.00 target price on shares of Supernus Pharmaceuticals and gave the company a “hold” rating in a research note on Monday, July 2nd. Stifel Nicolaus lifted their target price on shares of Supernus Pharmaceuticals from $50.00 to $60.00 and gave the company a “buy” rating in a research note on Friday, May 25th. Jefferies Financial Group lifted their target price on shares of Supernus Pharmaceuticals from $55.00 to $58.00 and gave the company a “buy” rating in a research note on Thursday, August 9th. Finally, Cantor Fitzgerald set a $56.00 target price on shares of Supernus Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, August 8th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have issued a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $54.09.

SUPN opened at $48.85 on Wednesday. The company has a debt-to-equity ratio of 0.82, a quick ratio of 2.54 and a current ratio of 2.74. Supernus Pharmaceuticals has a fifty-two week low of $33.30 and a fifty-two week high of $61.25. The firm has a market cap of $2.55 billion, a P/E ratio of 38.77 and a beta of 0.83.

Supernus Pharmaceuticals (NASDAQ:SUPN) last released its earnings results on Tuesday, August 7th. The specialty pharmaceutical company reported $0.57 earnings per share for the quarter, beating analysts’ consensus estimates of $0.43 by $0.14. Supernus Pharmaceuticals had a net margin of 24.17% and a return on equity of 30.57%. The company had revenue of $99.54 million for the quarter, compared to analysts’ expectations of $101.01 million. equities analysts expect that Supernus Pharmaceuticals will post 1.98 earnings per share for the current year.

In other Supernus Pharmaceuticals news, VP Stefan K.F. Schwabe sold 60,000 shares of the business’s stock in a transaction on Monday, June 18th. The shares were sold at an average price of $54.39, for a total value of $3,263,400.00. Following the sale, the vice president now owns 21,967 shares in the company, valued at approximately $1,194,785.13. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Gregory S. Patrick sold 35,000 shares of the business’s stock in a transaction on Monday, July 2nd. The stock was sold at an average price of $56.63, for a total transaction of $1,982,050.00. Following the completion of the sale, the chief financial officer now owns 75,975 shares in the company, valued at approximately $4,302,464.25. The disclosure for this sale can be found here. In the last quarter, insiders sold 110,000 shares of company stock worth $6,144,826. Corporate insiders own 6.20% of the company’s stock.

Hedge funds have recently made changes to their positions in the business. Creative Planning lifted its stake in Supernus Pharmaceuticals by 27.1% in the 2nd quarter. Creative Planning now owns 20,719 shares of the specialty pharmaceutical company’s stock worth $1,240,000 after purchasing an additional 4,415 shares in the last quarter. Shaker Investments LLC OH raised its position in shares of Supernus Pharmaceuticals by 16.4% during the 2nd quarter. Shaker Investments LLC OH now owns 49,642 shares of the specialty pharmaceutical company’s stock valued at $2,971,000 after buying an additional 7,002 shares in the last quarter. Reliance Trust Co. of Delaware purchased a new stake in shares of Supernus Pharmaceuticals during the 2nd quarter valued at about $243,000. Cynosure Advisors LLC raised its position in shares of Supernus Pharmaceuticals by 55.0% during the 2nd quarter. Cynosure Advisors LLC now owns 8,260 shares of the specialty pharmaceutical company’s stock valued at $494,000 after buying an additional 2,930 shares in the last quarter. Finally, SevenBridge Financial Group LLC purchased a new stake in shares of Supernus Pharmaceuticals during the 2nd quarter valued at about $113,000. Institutional investors and hedge funds own 97.42% of the company’s stock.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy.

Further Reading: Asset Allocation, Balancing Your Investments

Analyst Recommendations for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit